Rigel Pharmaceuticals reported $55.31M in Sales Revenues for its fiscal quarter ending in September of 2024.





Sales Change Date
Agenus USD 33.7M 500K Mar/2026
Amgen USD 10.4B 300M Sep/2026
Anika Therapeutics USD 30.62M 2.8M Dec/2025
Arrowhead Research USD 450.82M 375.59M Sep/2026
AstraZeneca USD 16.21B 830M Sep/2026
BioMarin Pharmaceutical USD 1.03B 40M Sep/2026
Bristol-Myers Squibb USD 13.07B 100M Sep/2026
Celldex Therapeutics USD 400K 378K Sep/2026
Daiichi Sankyo JPY 592.49B 17.75B Sep/2026
Eli Lilly USD 24.4B 1.43B Sep/2026
Halozyme Therapeutics USD 492.97M 11.97M Sep/2026
Heron Therapeutics USD 40.59M 2.38M Dec/2025
Intrexon USD 717K 511K Jun/2024
Ionis Pharmaceuticals USD 243M 25M Sep/2026
Karyopharm Therapeutics USD 35.07M 987K Mar/2026
Ligand Pharmaceuticals USD 78.75M 4.95M Sep/2026
MacroGenics USD 32.83M 12.03M Jun/2026
Neurocrine Biosciences USD 1.12B 161M Sep/2026
Pfizer USD 16.6B 1.57B Sep/2026
Regeneron Pharmaceuticals USD 5.12B 830M Sep/2026
Rigel Pharmaceuticals USD 55.31M 18.47M Sep/2024
Sangamo BioSciences USD 356K 125K Jun/2024
Ultragenyx Pharmaceutical USD 173M 41M Sep/2026
Veracyte USD 151.75M 1.43M Sep/2026